{
    "clinical_study": {
        "@rank": "100658", 
        "arm_group": {
            "arm_group_label": "Group 1", 
            "description": "Patient treated with Ciproxan without dilution treatment in daily clinical practice"
        }, 
        "brief_summary": {
            "textblock": "This study is a post-marketing surveillance in Japan to investigate the safety especially\n      focusing on injection site adverse events and efficacy in patients with Ciprofloxacin iv\n      administration without dilution in the daily practice.It is a local prospective and\n      observational study of patients who have received Ciproxan intravenously for sepsis,\n      secondary skin infections followed by superficial burn, post-surgical or post-traumatic,\n      pneumonia, peritonitis, cholecystitis, cholangitis, anthrax. A total of 500 patients are to\n      be enrolled and assessed during the period of treatment with Ciproxan."
        }, 
        "brief_title": "Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution", 
        "completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "condition": "Infection", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  - The mentioned bellow patients caused by the following bacteria which are sensitive\n             to this drug: Indicated microorganisms:Staphylococcus, Enterococcus, Bacillus\n             anthracis, Escherichia coli, Klebsiella , Enterobacter, Pseudomonas aeruginosa,\n             Legionella. Indications: Sepsis, Secondary skin infections (superficial burn,\n             operative wounds, trauma), Pneumonia, Peritonitis, Cholecystitis, Cholangitis,\n             Anthrax\n\n          -  The patients treated with this drug without dilution due to strict restriction of\n             fluid intake.\n\n          -  In hospitalized patients who retain consciousness ,and at the same time who are able\n             to report (such as vascular pain) side effects..\n\n        Exclusion Criteria:\n\n          -  Patients who are contraindicated based on the product label."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "7 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients who received Ciproxan iv administration without dilution in the daily practice\n        among those with sepsis, secondary infection due to trauma, burn, or surgical wound,\n        pneumonia, peritonitis, cholecystitis, cholangitis, and anthrax as the indications of this\n        drug."
            }
        }, 
        "enrollment": {
            "#text": "704", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01690559", 
            "org_study_id": "16516", 
            "secondary_id": "CIPRO-IV-2010"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patient treated with Ciproxan without dilution treatment in daily clinical practice", 
            "intervention_name": "Cipro (Ciprofloxacin, BAYQ3939)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ciprofloxacin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ciprofloxacin", 
            "sepsis", 
            "infection", 
            "pneumonia", 
            "peritonitis", 
            "cholecystitis", 
            "cholangitis", 
            "anthrax"
        ], 
        "lastchanged_date": "September 19, 2012", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse drug reactions (ADRs) and serious adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "After 8 days"
            }, 
            {
                "measure": "Clinical efficacy by four grade (Response, Minor Response, No Response, and Indeterminable) at an investigator discretion", 
                "safety_issue": "No", 
                "time_frame": "After 8 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01690559"
        }, 
        "responsible_party": {
            "name_title": "Medical Director", 
            "organization": "Bayer Yakuhin, Ltd"
        }, 
        "secondary_outcome": [
            {
                "measure": "ADR incidence rates classified by patient's background factors", 
                "safety_issue": "Yes", 
                "time_frame": "After 8 days"
            }, 
            {
                "measure": "Efficacy rate calculated with Response and Minor Response considered as responder", 
                "safety_issue": "No", 
                "time_frame": "After 8 days"
            }, 
            {
                "measure": "Efficacy rates classified by patient's background factors", 
                "safety_issue": "No", 
                "time_frame": "After 8 days"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2010", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2012"
    }
}